NERV logo

NERV
Minerva Neurosciences Inc

9,613
Mkt Cap
$338.84M
Volume
243,610.00
52W High
$12.46
52W Low
$1.15
PE Ratio
-0.29
NERV Fundamentals
Price
$7.83
Prev Close
$7.69
Open
$7.60
50D MA
$5.44
Beta
0.81
Avg. Volume
118,033.82
EPS (Annual)
-$34.67
P/B
-2.41
Rev/Employee
$0.00
$16.58
Loading...
Loading...
News
all
press releases
What is HC Wainwright's Forecast for NERV Q1 Earnings?
Minerva Neurosciences, Inc (NASDAQ:NERV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Minerva Neurosciences in a research note issued to...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results
Minerva Neurosciences (NASDAQ:NERV - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping...
MarketBeat·4d ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Upgraded to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Minerva Neurosciences from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·16d ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Shares Pass Above 50 Day Moving Average - Here's What Happened
Minerva Neurosciences (NASDAQ:NERV) Shares Pass Above Fifty Day Moving Average - What's Next...
MarketBeat·18d ago
News Placeholder
Minerva Neurosciences (NERV) to Release Earnings on Tuesday
Minerva Neurosciences (NASDAQ:NERV) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...
MarketBeat·26d ago
News Placeholder
Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update
Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest...
MarketBeat·27d ago
News Placeholder
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia
Minerva Neurosciences (NASDAQ:NERV) hosted a virtual key opinion leader (KOL) event focused on its development candidate roluperidone for negative symptoms in schizophrenia, outlining the clinical...
MarketBeat·1mo ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Above 50 Day Moving Average - What's Next?
Minerva Neurosciences (NASDAQ:NERV) Stock Price Crosses Above 50 Day Moving Average - Here's What Happened...
MarketBeat·2mo ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at Wall Street Zen
Wall Street Zen cut Minerva Neurosciences from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·2mo ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen raised Minerva Neurosciences from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
<
1
2
...
>

Latest NERV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.